EU PMCF Post-Market Clinical Follow-Up for Medical Devices
Last reviewed:
Post-Market Clinical Follow-Up (PMCF) is a continuous, proactive process of collecting clinical data from the real-world use of a device after it is placed on the market.
What is Post-Market Clinical Follow-Up under the EU MDR?
Post-Market Clinical Follow-Up (PMCF) is a continuous, proactive process of collecting clinical data from the real-world use of a device after it is placed on the market. PMCF is required under the European Medical Device Regulation (EU MDR), defined in Annex XIV, Part B. It is a crucial part of your Post-Market Surveillance (PMS) system, which monitors a medical device’s safety and performance once it has been CE Marked and placed on the EU market. Data gathered through PMCF supports continuous clinical evaluation and must be incorporated into the device’s Technical Documentation and Clinical Evaluation Report (CER). It is also a vital component of your quality management system (QMS).
The primary goals of PMCF are to confirm the long-term safety and performance of the device, monitor the ongoing acceptability of known risks, identify any new risks or side effects, and ensure that the device's benefit-risk balance remains acceptable. PMCF also helps detect off-label use and verify that the device continues to be used as intended.
Planning your PMCF activities
The first step in the PMCF process is to develop a structured PMCF Plan. This document outlines the strategy and methods you will use to gather clinical data. PMCF data can include user surveys, literature reviews, registry data, or formal PMCF studies. You must explain why each method was selected and how it aligns with the specific safety and performance requirements for your device. The detailed structure and content of the PMCF Plan is published in MDCG 2020-7 “Post-market clinical follow-up (PMCF) Plan Template."
The scope of your PMCF activities should be proportionate to the device’s risk class and type. Manufacturers should perform a gap analysis to identify the clinical data they need, after the devices have been placed on the EU market. The PMCF Plan must include how to select appropriate data collection methods and sources and how to update risk management and CER accordingly. Manufacturers of lower-risk devices may justify limited or no PMCF activities in their PMCF Plan, provided they present sufficient rationale. High-risk devices typically require more comprehensive PMCF plans and PMCF studies to demonstrate the device’s safety and performance.
PMCF reporting requirements
Once implemented, the results of your PMCF activities will be summarized in a PMCF Report, which is part of your ongoing updates to the CER. For Class III and Class IIb implantable devices, the PMCF report should be updated annually. Other devices should update it every 2-5 years, depending on the device class, or as needed, if PMS data raises new questions or gaps regarding device safety and performance or suggests an emerging risk or side effect. PMCF data is also summarized in the PMS Report or Periodic Safety Update Report (PSUR), depending on your device class. The detailed content of the PMCF Report is published in MDCG 2020-8 “Post-market clinical follow-up (PMCF) Report Template."
Regulatory authority and source of truth
This service sits within the current requirements administered by the relevant regulator. Use that glossary entry for the authority's remit, official portal, and contact points; use this page for the task-specific workflow and deliverables.
Start planning your Post-Market Clinical Follow-up
Our regulatory and clinical experts scope and run PMCF that satisfies MDR and Notified Body expectations, from a plan built from scratch to PMCF studies.

Frequently asked questions
The templates published by the European Commission in 2020, MDCG 2020-7 and MDCG 2020-8, describe the expected content for traceability to other parts of your Technical Documentation and indirectly demonstrate how PMCF should be included in your QMS and QMS processes. Because Notified Bodies are using MDCG documents as the expected level of evidence, it is strongly recommended to include these templates in your PMCF procedure and make sure that the input and output from PMCF activities is linked within your QMS.
You will need to run a PMCF study any time your existing data is not enough to fully confirm long-term safety and performance due to residual risks or uncertainty about long-term device performance. For example, you should consider a PMCF study if your device uses new materials, innovative technologies, or has a novel design or indication. It is also important if your device is used in high-risk situations, such as in critical anatomical areas or with new or high-risk populations. Other triggers can include significant design changes, unexpected or adverse events in post-market use, or when your CE mark was based on equivalence to another device. Your Notified Body can also request or require PMCF studies to address specific objectives. MEDDEV 2.12/2 rev.2 provides more potential indications for PMCF studies.
If your device is low risk or the technology is well established, you may not need to perform PMCF. Nevertheless, you must still produce a PMCF plan and PMCF report in which you must justify your case for foregoing PMCF activities. As part of the Technical Documentation Review, your Notified Body will scrutinize the adequacy of your justification and may still require you to perform PMCF.
The PMSR and the PSUR are documents that summarize PMS activities, but they apply to different classes of devices and have different content and reporting requirements. The PMSR is a lighter summary intended for Class I devices, while the PSUR is a comprehensive report required for Class IIa, IIb and Class III devices that involves formal submission and review by Notified Bodies. Manufacturers of class IIb and class III devices shall update the PSUR at least annually.
Single Process,
Multiple Markets
When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.
Let's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us










